Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

verfora sa - hydrocortisonum - lipocrème - hydrocortisoni acetas 5 mg corresp. hydrocortisonum 4.3 mg, aromatica, conserv.: triclosanum, chlorhexidini dihydrochloridum, excipiens ad unguentum pro 1 g. - dermatoses inflammatoires non infectées - synthetika

Svizzera - francese - Swissmedic (Swiss Agency for Therapeutic Products)

verfora sa - hydrocortisonum - mousse - hydrocortisoni acetas 5 mg corresp. hydrocortisonum 4,3 mg, antiox.: e 320, conserv.: triclosanum, chlorhexidini dihydrochloridum, excipiens à emulsionem pour 1 g de la. propellentia. - dermatoses inflammatoires non infectées - synthetika

Svizzera - tedesco - Swissmedic (Swiss Agency for Therapeutic Products)

verfora sa - hydrocortisonum - hydrocrème - hydrocortisoni acetas 5 mg endwerte. hydrocortisonum 4.3 mg, antiox.: e 320, conserv.: triclosanum, chlorhexidini dihydrochloridum, excipiens ad-salbe für 1 g. - entzündliche hauterkrankungen, die nicht infiziert - synthetika

Svizzera - tedesco - Swissmedic (Swiss Agency for Therapeutic Products)

verfora sa - hydrocortisonum - lipocrème - hydrocortisoni acetas 5 mg endwerte. hydrocortisonum 4.3 mg, conserv.: triclosanum, chlorhexidini dihydrochloridum, excipiens ad-salbe für 1 g. - entzündliche hauterkrankungen, die nicht infiziert - synthetika

Svizzera - tedesco - Swissmedic (Swiss Agency for Therapeutic Products)

verfora sa - hydrocortisonum - schaum - hydrocortisoni acetas 5 mg endwerte. hydrocortisonum 4.3 mg, antiox.: e 320, conserv.: triclosanum, chlorhexidini dihydrochloridum, excipiens zu emulsionem für 1 g. propellentia. - entzündliche hauterkrankungen, die nicht infiziert - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

a. menarini industrie farmaceutiche riunite s.r.l. - corticosteroidi, attivi (gruppo iii) - corticosteroidi, attivi (gruppo iii)

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

a. menarini industrie farmaceutiche riunite s.r.l. - beclometasone - beclometasone

Australia - inglese - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - tolnaftate, quantity: 0.89 mg/g - spray, pressurised - excipient ingredients: butane; ppg-12-buteth-16; propane; isobutane; butylated hydroxytoluene; purified talc; ethanol - indicated for the topical treatment of skin infections due to common pathogenic fungi, including trichophyton rubrum, trichophyton mentagrophytes (t.gypseum), trichophyton tonsurans and epidermophyton floccosum. tinaderm powder and powder spray are recommended for adjunctive use with tinaderm cream or solution in fungal infections of interiginous and other naturally moist skin areas in which drying may enhance the therapeutic response. tinaderm powder and powder spray may also be used alone in simple cases of mild infection that respond to treatment with an antifungal powder and measures that promote skin hygiene.,following complete remission, tinaderm powder and powder spray alone may be continued to maintain remission or reduce the risk of reinfection.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - tolnaftate, quantity: 10 mg/g - powder, dusting - excipient ingredients: silicon dioxide; purified talc - topical treatment of skin infections due to common pathogenic fungi, including trichophyton rubrum, trichophyton mentaggrophyton (t.gypseum), trichophyton tonsurans and epidermophyton floccosum. tinaderm powder is recommended for adjunctive use with tinaderm cream or solution in fungal infections of intertriginous and other naturally moist skin areas in which drying may enhance the therapeutic response. tinaderm powder may also be used alone in simple cases of mild infection that respond to treatment with antifungal powder and measures that promote skin hygiene. following complete remission, tinaderm powder alone may be contineud to maintain or reduce the risk of infection.

Stati Uniti - inglese - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - calcipotriene (unii: 143nq3779b) (calcipotriene - unii:143nq3779b) - calcipotriene cream, 0.005%, is indicated for the treatment of plaque psoriasis. the safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established. calcipotriene cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. it should not be used by patients with demonstrated hypercalcemia or evidence of vitamin d toxicity. calcipotriene cream should not be used on the face. skin protectant for the treatment and/or prevention of diaper rash. temporarily protects and helps relieve chapped or cracked skin. condition worsens symptoms last more than 7 days or clear up and occur again within a few days